# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k132515

B. Purpose for Submission: New Device

C. Measurand: Intact Parathyroid Hormone (PTH)

D. Type of Test: Quantitative, two-site sandwich chemiluminescent immunoassay

E. Applicant: Diasorin Inc.

F. Proprietary and Established Names: LIAISON® N-TACT® PTH Gen II LIAISON® N-TACT® PTH Gen II Control Set LIAISON® N-TACT® PTH Gen II Calibration Verifiers

# G. Regulatory Information:

1. Regulation section: 21 CFR 862.1545, Parathyroid Hormone Test System 21 CFR 862.1660, Quality Control Material (assayed and unassayed)

2. Classification: Class II Class I, reserved

3. Product code:

CEW JJX

4. Panel: Clinical Chemistry (75)

# H. Intended Use:

1. Intended use(s): See Indication(s) for use below.

2. Indication(s) for use:

The LIAISON® N-TACT® PTH Gen II is an in vitro chemiluminescent immunoassay (CLIA) intended for the quantitative determination of intact human parathyroid hormone in serum, EDTA and Lithium Heparin plasma samples. Measurements of parathyroid hormone levels are used in the differential diagnosis of hypercalcemia and hypocalcemia resulting from disorders of calcium metabolism. The test is to be performed on the LIAISON XL analyzer.

The LIAISON® N-TACT® PTH Gen II Control Set is intended for use as assayed quality control samples to monitor the accuracy and precision of the DiaSorin LIAISON® N-TACT® PTH Gen II assay.

The LIAISON® N-TACT® PTH Gen II Calibration Verifiers are assayed quality control materials intended for the quantitative verification of calibration and reportable range of the LIAISON® N-TACT® PTH Gen II assay.

3. Special conditions for use statement(s): For prescription use only.

4. Special instrument requirements: For use on the DiaSorin LIAISON® XL Analyzer

# I. Device Description:

The LIAISON® N-TACT® PTH Gen II Assay in an in vitro diagnostic device consisting of reagents provided in individual compartments within a plastic container identified as the LIAISON Reagent Integral. The Reagent Integral contains:

Magnetic particles coated with goat polyclonal antibody against 39-84 PTH peptide, BSA, phosphate buffer, surfactant, $0 . 1 \%$ ProClin 300 and $0 . 0 5 \%$ gentamicin sulfate.   
Conjugate: Goat polyclonal antibody against 1-34 PTH peptide conjugated to an isoluminol derivative, in phosphate buffer, BSA, surfactant, $0 . 1 \%$ ProClin 300 and $0 . 0 5 \%$ gentamicin sulfate.   
Assay buffer: Phosphate buffer, BSA, surfactant, blockers, $0 . 0 9 \%$ ProClin 300 and $0 . 0 4 5 \%$ gentamicin sulfate. LIAISON® N-TACT® PTH Gen II Calibrators   
Two vials each of Calibrator 1 and Calibrator 2 are included in the reagent kit. The calibrators consist of phosphate buffer, 1-84 PTH, surfactants, BSA, EDTA and $0 . 2 \%$ ProClin 300. Calibrator 1 is manufactured to have a target intact PTH level of $1 5 ~ \mathrm { p g / m L }$ and Calibrator 2 is manufactured to have a target intact PTH level of $1 3 0 0 ~ \mathrm { p g / m L }$ . LIAISON® N-TACT® PTH Gen II Control set contains;   
2 levels controls containing $80 \%$ human plasma spiked with 1-84 PTH, and preservatives; 4 vials each level; lyophilized   
Control Level 1 is manufactured to have a target intact PTH level of $2 0 ~ \mathrm { p g / m L }$ Control Level 2 is manufactured to have a target intact PTH level of $3 0 0 \mathrm { p g / m L }$ LIAISON® N-TACT® PTH Gen II Calibration Verifier set contains:   
4 levels containing $80 \%$ human plasma spiked with 1-84 PTH, with preservative, 1 vial each level, lyophilized   
The target concentration for Cal verifier A is $1 0 \ : \mathrm { p g / m L }$ .   
The target concentration for Cal verifier B is $1 5 0 ~ \mathrm { p g / m L }$ .   
The target concentration for Cal verifier C is $6 5 0 ~ \mathrm { p g / m L }$ .   
The target concentration for Cal verifier D is $1 6 0 0 ~ \mathrm { p g / m L }$ .

Each serum/plasma donor unit used in the preparation of these products has been tested by an U.S. FDA approved method and found non-reactive for the presence of the antibody to Human Immunodeficiency Virus 1 and 2, the Hepatitis B surface antigen, and the antibody to Hepatitis C.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Siemens ADVIA CENTAUR INTACT Parathyroid Hormone (iPTH) Assay LIAISON® N-TACT® PTH Control Set LIAISON® N-TACT® PTH Calibration Verifiers

2. Predicate 510(k) number(s): k020217 k033426 k093498

3. Comparison with predicate:

# Reagent

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>DeviceLIAISON® N-TACT® PTHGen II</td><td rowspan=1 colspan=1>PredicateADVIA Centaur iPTH(K020217)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For in vitro quantitativedetermination of intacthuman parathyroid hormone</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Two-point calibration</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Goat Polyclonal</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent storage</td><td rowspan=1 colspan=1>On-board or in refrigeratorat 2-8°</td><td rowspan=1 colspan=1>Same</td></tr></table>

Reagent   

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>DeviceLIAISON® N-TACT® PTHGen II</td><td rowspan=1 colspan=1>PredicateADVIA Centaur iPTH(K020217)</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>3.0 -1900 pg/mL</td><td rowspan=1 colspan=1>2.5-1900 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Sample Matrix</td><td rowspan=1 colspan=1>EDTA Plasma, Serum, SSTserum ,and Lithium HeparinPlasma</td><td rowspan=1 colspan=1>EDTA Plasma, Serum</td></tr><tr><td rowspan=1 colspan=1>Sample Size</td><td rowspan=1 colspan=1>150 μL</td><td rowspan=1 colspan=1>200 μL</td></tr><tr><td rowspan=1 colspan=1>Open Storage on analyzer</td><td rowspan=1 colspan=1>56 days</td><td rowspan=1 colspan=1>28 days</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>2 levels, included in kit</td><td rowspan=1 colspan=1>2 levels, not included in kit</td></tr><tr><td rowspan=1 colspan=1>Calibration interval</td><td rowspan=1 colspan=1>28 days</td><td rowspan=1 colspan=1>14 days</td></tr><tr><td rowspan=1 colspan=1>Reference Range</td><td rowspan=1 colspan=1>14.5-87.1 pg/mL</td><td rowspan=1 colspan=1>11.1-79.5 pg/mL</td></tr></table>

Control   

<table><tr><td rowspan=1 colspan=3>Similarities and differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>DeviceLIAISON®N-TACT® PTHGen II Control set</td><td rowspan=1 colspan=1>PredicateLIAISON® N-TACT® PTHControl set (k033426)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Quality control materials forthe PTH assay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>2 levels: low and high</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>Store at 2-8°C until ready touse</td><td rowspan=1 colspan=1>Same</td></tr></table>

Calibration Verifiers   

<table><tr><td rowspan=1 colspan=3>Similarities and differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>DeviceLIAISON® N-TACT® PTHGen II Calibration Verifierset</td><td rowspan=1 colspan=1>PredicateLIAISON® N-TACT® PTHGen II Calibration Verifier(k093498)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Assayed quality controlmaterials for thequantitative verification ofthe PTH calibration.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>4 levels, lyophilized</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>Store at 2-8°C until ready touse</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Volume</td><td rowspan=1 colspan=1>2.0 mL</td><td rowspan=1 colspan=1>Same</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

· EP5-A2, Evaluation of Precision Performance of Quantitative Measurement Methods; Approved CLSI Guideline   
· EP6-A, Evaluation of Linearity of Quantitative Analytical Methods; Approved CLSI Guideline   
· EP7-A2, Interference Testing in Clinical Chemistry; Approved CLSI Guideline   
· EP9-A2-IR, Method Comparison and Bias Estimation Using Patient Samples; Approved CLSI Guideline   
· CLSI Guideline EP17-A2 Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures   
· CLSI Guideline C28-A3, Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory

# L. Test Principle:

The LIAISON® N-TACT® PTH Gen II assay is a modified two-step, two-site sandwich assay that uses two goat polyclonal antibodies for capture and detection of intact PTH. Results are determined by a 2 point calibration conversion of the master curve to a working curve. The light signal is measured by a photomultiplier as relative light units (RLU) and is proportional to the concentration of intact PTH present in the calibrators, controls or samples.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

# a. Precision/Reproducibility:

Precision testing was performed following CLSI Guideline EP5-A2. A coded panel comprised of 7 frozen EDTA plasma samples spanning the assay range and 2 lots of LIAISON® N-TACT® PTH Gen II controls (2 levels) were tested in the study. The precision panel samples and kit controls were tested on two lots of $\mathrm { \Delta L I A I S O N } ^ { \textregistered }$ NTACT® PTH Gen II in two replicates per run, 2 runs per day for 20 operating days for a total of 160 replicate results per sample. The 20 day results are summarized for the combined reagent lot numbers as sample mean PTH concentration in $\mathrm { { \sf p g / m L } }$ , standard deviations and coefficient of variation $( \% C V )$ for between lot and Total across lots. Precision results are summarized in the table below:

<table><tr><td rowspan=2 colspan=1>Sample ID</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=1>MeanPTH</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Total(Across Lots)</td></tr><tr><td rowspan=1 colspan=1>(pg/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Lot 1 Kit Control1</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>19.3</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.65</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>Lot 1 Kit Control 2</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>9.27</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>8.84</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=1 colspan=1>Lot 2 Kit Control1</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>18.5</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>3.1%</td></tr><tr><td rowspan=1 colspan=1>Lot 2 Kit Control 2</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>252</td><td rowspan=1 colspan=1>10.59</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>9.05</td><td rowspan=1 colspan=1>3.6%</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma 1</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.53</td><td rowspan=1 colspan=1>4.2%</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma 2</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>34.5</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>1.38</td><td rowspan=1 colspan=1>4.0%</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma 3</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>86.2</td><td rowspan=1 colspan=1>1.68</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>3.07</td><td rowspan=1 colspan=1>3.6%</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma 4</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>156.1</td><td rowspan=1 colspan=1>5.25</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>5.54</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma 5</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>605</td><td rowspan=1 colspan=1>24.62</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>19.37</td><td rowspan=1 colspan=1>3.2%</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma 6</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>1348</td><td rowspan=1 colspan=1>46.58</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>44.06</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma 7</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>1477</td><td rowspan=1 colspan=1>84.06</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>40.62</td><td rowspan=1 colspan=1>2.8%</td></tr></table>

# b. Linearity/assay reportable range:

One patient sample for each sample type (Serum, SST serum, EDTA and Lithium Heparin plasma) was spiked with PTH 1-84 to achieve PTH levels above the measuring range of the assay and diluted with a normal PTH patient sample of the same type to achieve PTH levels in the lower portion of the measuring range. In order to achieve PTH values in the very low range, the low normal sample was further diluted with sample diluent (containing no PTH) to levels near the claimed LoQ of the assay. Each of the 18 concentrations for each sample type was tested in triplicate on the LIAISON XL analyzer with one lot of reagent. The resulting regression equations for each sample type are summarized below:

Serum: $\mathrm { y } = 0 . 9 7 6 7 \mathrm { x } - 3 . 6 2 4$ ; $\mathrm { R } ^ { 2 } = 0 . 9 9 8 2$ SST Serum: $y = 0 . 9 7 4 2 \mathrm { x } + 3 . 8 5 6$ ; $\operatorname { R } ^ { 2 } = 0 . 9 9 8 7$ EDTA plasma: $\mathrm { y } { = } 1 . 0 1 2 \mathrm { x } - 4 . 1 2 7$ ; $\operatorname { R } ^ { 2 } = 0 . 9 9 8 3$ Lithium Heparin plasma: $\mathrm { y } = 0 . 9 4 6 1 \mathrm { x } + 3 . 6 9 6 ; \mathrm { R } ^ { 2 } = 0 . 9 9 9 2$

The linearity results support the claimed measuring range of this device (3.0-1900 $\mathrm { p g / m L ) }$ for serum, SST serum, EDTA plasma, and Lithium Heparin plasma samples.

# Hook Effect Study

The sponsor performed a hook effect study to determine if there is high dose hook effect.

Testing was performed with 1 kit lot of LIASON N-TACT PTH Gen II. A zero sample was spiked with 1-84 PTH (NIBSC 95/646) to achieve PTH concentrations several times above the assay measuring range of $1 9 0 0 \mathrm { p g / m L }$ . The spiked samples were measured in triplicate. The study demonstrated that no high dose hook effect was observed at values up to $1 , 0 0 0 , 0 0 0 \mathrm { p g / m L }$ of 1-84 PTH.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability   
The LIAISON PTH N-TACT Calibrators are traceable to master standards which are prepared from the WHO International standard PTH (1-84) human recombinant. (NIBSC 95/646)

# Value Assignment

Calibrator: The concentration of the kit calibrators are assigned through an internal procedure. The LIAISON N-TACT PTH Gen II calibrators are tested on a minimum of 3 LIAISON XL Analyzers, in a minimum of 5 assay runs with six replicates per vial resulting in a minimum of 30 individual replicate results used for final value range assignment. The LIAISON N-TACT PTH Gen II kit calibrators have the following target intact PTH values:

Level 1: $1 5 ~ \mathrm { p g / m L }$ Level 2: $1 3 0 0 ~ \mathrm { p g / m L }$

Control: A minimum of 10 vials of each level of control are used in the final range assignment. The LIAISON N-TACT PTH Gen II Control Set are tested on a minimum of 3 LIAISON XL Analyzers, using 2 different assay kit lots, in a minimum of 5 assay runs. Two vials of each level are tested in each of the 5 separate assay runs with four replicates per vial resulting in a minimum of 40 individual replicate results used for final value assignment. The LIAISON N-TACT PTH Gen II Control Set has the following target intact PTH ranges:

Control Level 1: $2 0 ~ \mathrm { p g / m L }$ Control Level 2: $3 0 0 ~ \mathrm { p g / m L }$

Calibration Verifiers: The 4 levels of calibration verifiers (A-D) are intended to span the assay range of the LIAISON N-TACT PTH Gen II assay. The target concentrations for each lot of calibration verifiers are assigned at the manufacturer by testing a minimum of 12 vials of each level of calibration verifier on 2 different LIAISON N-TACT PTH Gen II assay kit lots on a minimum of 4 LIAISON XL Analyzers, in a minimum of 6 runs with 4 replicates per vial resulting in a minimum of 48 individual replicate results per control level for final value assignment. The target concentrations for cal verifiers are:

Cal verifier A: $1 0 \ : \mathrm { p g / m L }$ Cal verifier B: $1 5 0 ~ \mathrm { p g / m L }$ Cal verifier C: $6 5 0 ~ \mathrm { p g / m L }$ Cal verifier D $: 1 6 0 0 \ : \mathrm { p g / m L }$

# Stability

Reagent: On-board stability for the LIAISON N-TACT PTH Gen II assay was established by real time studies on the LIAISON XL Analyzer. The stability study protocol and the acceptance criteria have been found acceptable. The on-board stability of the reagent is 56 days with a calibration interval of 28 days. The LIAISON N-TACT PTH Gen II assay reagent is stable until the date printed on the label when stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ .

Control: On-board stability for the LIAISON N-TACT PTH Gen II Control Set and the LIAISON N-TACT PTH Gen II Calibrators was established by real time studies on the LIAISON XL Analyzer. The stability study protocol and the acceptance criteria have been found acceptable. The on-board stability of the reconstituted calibrators is 7 hours. The on-board stability of the reconstituted controls is 8 hours. The reconstituted controls are stable for 7 hours at room temperature or 8 hours at 2- $8 \mathrm { ^ \circ C }$ .The lyophilized LIAISON N-TACT PTH Gen II Control Set is stable until the date printed on the label when stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ .

Calibrator: On-board stability for the LIAISON N-TACT PTH Gen II Calibrators was established by real time studies on the LIAISON XL Analyzer. The stability study protocol and the acceptance criteria have been found acceptable. The on-board stability of the reconstituted calibrators is 7 hours. The reconstituted calibrators are stable for 48 hours at $2 { - } 8 ^ { \circ } \mathrm { C } .$ .The lyophilized LIAISON N-TACT PTH Gen II Calibrators is stable until the date printed on the label when stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ .

Calibration Verifiers: Stability for the LIAISON N-TACT PTH Gen II Calibration Verifiers was established by real time studies on the LIAISON XL. The stability study protocol and the acceptance criteria have been found acceptable. The DiaSorin LIAISON N-TACT PTH GEN II Calibration Verifiers are stable until the expiration date on the vials when stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ . Reconstituted calibration verifiers are stable for 7 hours at room temperature or 8 hours at $2 { - } 8 \ ^ { \circ } \mathrm { C }$ . Remaining calibration verifier material should be aliquoted and stored frozen at $\mathrm { - 2 0 ~ ^ { \circ } C }$ . Calibration verifiers are stable through 1 freeze thaw cycle.

# d. Detection limit:

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined according to CLSI EP17-A2.

Limit of Blank (LoB) : Five blank EDTA plasma samples were tested on two analyzers, with two reagent lots over six runs (2 replicates/sample run) on three days for a total of 60 results per reagent lot.

Limit of Detection (LoD): Four EDTA plasma samples in the range of the mean LoB to 4 times the mean LoB were tested with the LIAISON $^ \mathrm { \textregistered }$ N-TACT $\textsuperscript { \textregistered }$ PTH Gen II assay on two analyzers with two reagent lots , over six runs (2 replicates/ sample/run) over three days yielding a total of 96 results.

Limit of Quantitation (LoQ): Nine EDTA plasma samples in the range of 0 to 10 $\mathrm { { \ p g / m L } }$ were tested on two analyzers with two reagent lots over six runs (2 replicates/sample run) and three days, for a total of 144 results. LoQ is defined as the lowest concentration with an inter-assay precision of $\leq 2 0 \%$ CV.

The following detection limits results were determined with the LIAISON® NTACT® PTH Gen II Assay:

<table><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>LoQ</td></tr><tr><td rowspan=1 colspan=1>≤ 0.5 pg/mL</td><td rowspan=1 colspan=1>1.5 pg/mL</td><td rowspan=1 colspan=1>3.0 pg/mL</td></tr></table>

The claimed measuring range of the assay is $3 . 0 - 1 9 0 0 \mathrm { p g / m L }$

# e. Analytical specificity:

Endogenous Interferent Study:

The potential interferents listed below were tested at two PTH levels in EDTA Plasma (70 and $1 5 0 ~ \mathrm { p g / m L } )$ ). Each sample was spiked with the respective interferent at the concentrations shown below. The spiked samples were compared against controls containing no interferent. The two sets of matched spiked and unspiked samples containing each interferent were tested in 12 replicates using one reagent lot. The sponsor defines non-significant interference as results within $\pm 1 0 \%$ of the control value. The substances listed below were found to cause no significant interference in the LIAISON® N-TACT® PTH Gen II at the highest concentration listed below.

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Highest Concentration atwhich no significantinterference (≥±10%)wasobserved</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (conjugated)</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (unconjugated)</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>3,000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>12 g/dL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor (RF)</td><td rowspan=1 colspan=1>612 IU/L</td></tr><tr><td rowspan=1 colspan=1>Human Anti-mouseantibody (HAMA)</td><td rowspan=1 colspan=1>2670 ng/mL</td></tr></table>

# Drug Interference Study:

A drug interference study was performed to determine whether the presence of exogenous substances such as common pharmaceutical compounds may interfere with the LIAISON N-TACT PTH Gen II results. All interferents were tested with two EDTA plasma samples with PTH target concentrations of approximately $7 0 \ : \mathrm { p g / m L }$ and 150 $\mathrm { p g / m L }$ . Each sample level was spiked with the respective interferent at levels indicated in the table below. The same samples without interferent were tested as controls. The two sets of matched spiked and unspiked samples were tested in 12 replicates on 1 lot of the LIAISON N-TACT PTH Gen $\mathrm { I I }$ assay. The sponsor defines non-significant interference as results within $\pm 1 0 \%$ of the control value. The substances listed below were found to cause no significant interference in the LIAISON® N-TACT® PTH Gen II at the highest concentration listed below.

<table><tr><td rowspan=1 colspan=1>Drug/Substance</td><td rowspan=1 colspan=1>Highest Concentration atwhich no significantinterference (≥±10%)wasobserved</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>0.2 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic Acid</td><td rowspan=1 colspan=1>0.65 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Salicylic Acid</td><td rowspan=1 colspan=1>0.6mg/mL</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>0.5mg/mL</td></tr><tr><td rowspan=1 colspan=1>Alendronate</td><td rowspan=1 colspan=1>0.08mg/mL</td></tr><tr><td rowspan=1 colspan=1>Etidronate</td><td rowspan=1 colspan=1>1.05mg/mL</td></tr><tr><td rowspan=1 colspan=1>Pamidronate</td><td rowspan=1 colspan=1>0.18mg/mL</td></tr><tr><td rowspan=1 colspan=1>Risedronate</td><td rowspan=1 colspan=1>0.06mg/mL</td></tr><tr><td rowspan=1 colspan=1>Vitamin D2</td><td rowspan=1 colspan=1>240 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Vitamin D3</td><td rowspan=1 colspan=1>240 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Calitriol</td><td rowspan=1 colspan=1>1 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Alfacalcidol</td><td rowspan=1 colspan=1>2.5 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Biotin</td><td rowspan=1 colspan=1>1 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Calcium Acetate</td><td rowspan=1 colspan=1>0.4 mg/mL</td></tr><tr><td rowspan=1 colspan=1>CalciumCitrate</td><td rowspan=1 colspan=1>0.4 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Magnesium Chloride</td><td rowspan=1 colspan=1>0.4 mg/mL</td></tr><tr><td rowspan=1 colspan=1>AluminumSulfate</td><td rowspan=1 colspan=1>0.4 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Lanthanum Chloride</td><td rowspan=1 colspan=1>0.4 mg/mL</td></tr></table>

# Cross-Reactivity Study:

Cross-Reactivity of PTH fragment 7-84 was tested by spiking 3 concentration levels of either lyophilized PTH 7-84 antigen or WHO PTH 1-84 (NIBSC 95/646) into a zero sample and normalizing the recovery of PTH 7-84 to PTH 1-84 (NIBSC 95/646). Both the PTH 7-84 and PTH 1-84 were reconstituted in specimen diluent to a concentration of $1 0 { , } 0 0 0 \ \mathrm { p g / m L }$ and then diluted to three equivalent concentrations across the assay range. Samples were tested in triplicate on one kit lot of the LIAISON $^ \mathrm { \textregistered }$ N-TACT $\textsuperscript { \textregistered }$ PTH Gen II assay. The results demonstrated that all substances, except for PTH (7-84), showed less than $0 . 0 1 \%$ cross reactivity.

<table><tr><td rowspan=1 colspan=1>Cross-Reactant</td><td rowspan=1 colspan=1>SpikedConcentration</td><td rowspan=1 colspan=1>% CrossReactivity</td></tr><tr><td rowspan=1 colspan=1>PTH (7-84)</td><td rowspan=1 colspan=1>1200 pg/mL</td><td rowspan=1 colspan=1>53%</td></tr><tr><td rowspan=1 colspan=1>PTHI (1 34</td><td rowspan=1 colspan=1>200,000pg/mL</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr><tr><td rowspan=1 colspan=1>PTH(39- 68)</td><td rowspan=1 colspan=1>200,000pg/mL</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr><tr><td rowspan=1 colspan=1>PTH(44−68)</td><td rowspan=1 colspan=1>200,000pg/mL</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr><tr><td rowspan=1 colspan=1>PTH(39−84)</td><td rowspan=1 colspan=1>200,000pg/mL</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr><tr><td rowspan=1 colspan=1>PTH (5384</td><td rowspan=1 colspan=1>200,000pg/mL</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr><tr><td rowspan=1 colspan=1>Calcitonin</td><td rowspan=1 colspan=1>200,000pg/mL</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr><tr><td rowspan=1 colspan=1>C-Telopeptide(CTX-1)</td><td rowspan=1 colspan=1>200,000 pg/mL</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr><tr><td rowspan=1 colspan=1>Osteocalcin</td><td rowspan=1 colspan=1>200,000 pg/mL</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr></table>

The sponsor included the following limitation statement in the assay’s package insert:

The LIAISON® N-TACT® PTH Gen II assay will detect non-Intact PTH (1-84) such as PTH fragment (7-84).PTH fragment (7-84) may cause falsely elevated Intact PTH results in patients with abnormal renal function because these patients may have various concentrations of PTH fragment (7-84) in their blood. In patients with abnormal renal function please interpret the Intact PTH results with caution and do not make patient management decisions on the Intact PTH result alone.

f. Assay cut-off: Not Applicable

2. Comparison studies:

a. Method comparison with predicate device:

Following the CLSI EP9-A2 guidance document, the sponsor performed a method comparison study on 199 EDTA plasma samples from various sources. The samples included 127 presumed normal subjects, 43 hyperparathyroid patients, 26 renal dialysis patients and 3 samples that were spiked with PTH in order to span the complete assay range. All the samples were tested in singlicate using the Siemens ADVIA Centaurâ Intact PTH (predicate device) and the LIAISONâ N-TACT® PTH Gen II (candidate device). The samples tested ranged from $8 . 0 \ : \mathrm { p g / m L }$ to 1794 $\mathrm { { \ p g / m L } }$ . Passing & Bablok linear regression analyses were performed and gave the following results:

<table><tr><td rowspan=1 colspan=6>Passing &amp; Bablok Fit</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Interceptpg/mL</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Correlationcoefficient (r)</td></tr><tr><td rowspan=1 colspan=1>198</td><td rowspan=1 colspan=1>1.010</td><td rowspan=1 colspan=1>0.99 to 1.03</td><td rowspan=1 colspan=1>-1.5851</td><td rowspan=1 colspan=1>-3.11 to -0.44</td><td rowspan=1 colspan=1>0.9953</td></tr></table>

$b$ . Matrix comparison:

Sixty-five (65) matched patient sets of EDTA plasma, serum, SST serum, and Lithium Heparin plasma samples were tested to determine if these sample types provide equivalent results on the LIAISON® N-TACT® PTH Gen II assay. In order to obtain samples that spanned the measuring range of $3 . 0 { - } 1 9 0 0 \mathrm { p g / m L }$ , some of the samples were spiked. Each sample type was tested in singlicate using 1 lot of reagent. Passing & Bablok linear regression analyses were performed and gave the following results:

<table><tr><td rowspan=1 colspan=1>EDTA plasma vs.</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Interceptpg/mL</td><td rowspan=1 colspan=1>R^{2$</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.94 to 1.0</td><td rowspan=1 colspan=1>-2.45</td><td rowspan=1 colspan=1>0.9986</td></tr><tr><td rowspan=1 colspan=1>SST Serum</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>0.99 to 1.03</td><td rowspan=1 colspan=1>-2.25</td><td rowspan=1 colspan=1>0.9996</td></tr><tr><td rowspan=1 colspan=1>LithiumHeparin</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.97 to 1.01</td><td rowspan=1 colspan=1>-0.01</td><td rowspan=1 colspan=1>0.9991</td></tr></table>

Based on the data, the sponsor claims EDTA plasma, Lithium Heparin plasma, Serum, and SST serum are acceptable for this assay.

In the limitation section of the package insert, sponsor has the following limitation: “During routine monitoring of intact PTH levels, use the same specimen type throughout the monitoring period to avoid bias in the results.”

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable   
b. Clinical specificity: Not Applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable

4. Clinical cut-off: Not Applicable

5. Expected values/Reference range:

A reference range study was conducted according to the CLSI C28-A3 guideline. EDTA plasma samples from125 apparently healthy adults aged 21 - 70 years of age from mixed ethnic backgrounds $3 2 . 5 \%$ dark -skinned, $6 6 . 7 \%$ light-skinned and $0 . 8 \%$ unknown) with normal Total Calcium, TSH, Phosphorus, Magnesium, Creatinine, Alkaline Phosphatase and 25 OH Vitamin D values from the northern and southern regions of the U.S were used to establish the reference range.

LIAISON® N-TACT® PTH Gen II Reference Range for EDTA samples   

<table><tr><td rowspan=1 colspan=1>Population(n =125)</td><td rowspan=1 colspan=1>MedianPTH (pg/mL)</td><td rowspan=1 colspan=1>Observed Range2.5th to 97.5thPercentile</td></tr><tr><td rowspan=1 colspan=1>United States</td><td rowspan=1 colspan=1>34.00</td><td rowspan=1 colspan=1>14.5 - 87.1 pg/mL</td></tr></table>

It is recommended that each laboratory establish its own range of expected values.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.